Curr Breast Cancer Rep (2017) 9:183–187 DOI 10.1007/s12609-017-0250-y CLINICAL TRIALS (PF PEDDI, SECTION EDITOR) Evaluating the Role of Extended Aromatase Inhibitor Therapy in Early Hormone-Positive Breast Cancer 1 1 O. H. Vyas & V. G. Kaklamani Published online: 14 July 2017 Springer Science+Business Media, LLC 2017 . . Abstract Keywords Breast cancer Endocrine therapy Extended . . . Purpose of Review As adjuvant therapy for early-stage, endocrine therapy Aromatase inhibitors Adjuvant therapy hormone receptor-positive breast cancer has improved, late Hormone-positive breast cancer recurrences have become a significant issue. Endocrine therapies such as tamoxifen and aromatase inhibitors play a central role in reducing the risk of recurrence of hormone- Introduction positive breast cancers. However, the continued risk of breast cancer recurrence even with 5 years of adjuvant In 1896, Dr. George Beatson reported three cases of advanced AI therapy has led to interest in extended therapy. This breast cancer that improved after oophorectomy, the first re- review intends to discuss and analyze recent trials that port of successful endocrine therapy for breast cancer . have reported results with extending AI therapy beyond Since then, the management of breast cancer has become in- 5 years of treatment. creasingly complex, with selective
Current Breast Cancer Reports – Springer Journals
Published: Jul 14, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera